We are live on
!
Find out more
UOC
UBS O'Connor Portfolio holdings
AUM
$3.76B
1-Year Est. Return
62.41%
This Fund
S&P 500
This Quarter
Est. Return
+6.07%
1 Year Est. Return
+62.41%
3 Year Est. Return
+179.84%
5 Year Est. Return
+371.69%
10 Year Est. Return
+1,534.25%
AUM
$4.05B
AUM Growth
+$503M
(+14%)
Cap. Flow
+$330M
Cap. Flow
% of AUM
8.14%
Top 10 Holdings %
Top 10 Hldgs %
55.84%
Holding
654
New
120
Increased
131
Reduced
191
Closed
155
Avg Time Held Equity + Options
4.2
quarters
Top 10 Avg Time Held Equity + Options
1.2
quarters
Top 20 Avg Time Held Equity + Options
1.3
quarters
Avg Time Held Equity only
4.5
quarters
Top 10 Avg Time Held Equity only
1.2
quarters
Top 20 Avg Time Held Equity only
1.3
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kellanova
K
|
+$269M |
| 2 |
Stericycle Inc
SRCL
|
+$141M |
| 3 |
Marathon Oil Corporation
MRO
|
+$108M |
| 4 |
ChampionX
CHX
|
+$103M |
| 5 |
Spirit AeroSystems
SPR
|
+$95.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Equitrans Midstream Corporation Common Stock
ETRN
|
+$149M |
| 2 |
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
+$81.8M |
| 3 |
Southwestern Energy Company
SWN
|
+$56.7M |
| 4 |
Union Pacific
UNP
|
+$24.2M |
| 5 |
US Steel
X
|
+$20.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Energy | 20.91% |
| 2 | Technology | 19.62% |
| 3 | Healthcare | 14.36% |
| 4 | Industrials | 11.13% |
| 5 | Consumer Staples | 9.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
276
Perspective Therapeutics
CATX
$288M
| $947K | 0.02% |
70,923
-14,090
| -17% | -$187K |
2024 Q2
1 quarter
|
|
277
Agios Pharmaceuticals
AGIO
$1.84B
| $937K | 0.02% |
21,087
-8,926
| -30% | -$405K |
2022 Q4
7 quarters
|
|
278
Insulet
PODD
$9.7B
| $936K | 0.02% |
4,021
+374
| +10% | +$76.8K |
2023 Q3
4 quarters
|
|
279
Lionsgate Studios
LION
$3.3B
| $935K | 0.02% |
130,774
-19,226
| -13% | -$142K |
2024 Q2
1 quarter
|
|
280
KALA BIO
KALA
$5.42M
| $927K | 0.02% |
3,253
+302
| +10% | +$95.3K |
2024 Q1
2 quarters
|
|
281
Cooper Companies
COO
$10.6B
| $914K | 0.02% |
8,286
+2,997
| +57% | +$292K |
2024 Q1
2 quarters
|
|
282
DELISTED
SpringWorks Therapeutics
SWTX
| $914K | 0.02% |
28,513
-3,701
| -11% | -$138K |
2022 Q1
10 quarters
|
|
283
Alphatec Holdings
ATEC
$1.74B
| $902K | 0.02% |
162,297
+58,526
| +56% | +$449K |
2023 Q4
3 quarters
|
|
284
TG Therapeutics
TGTX
$8.46B
| $899K | 0.02% |
+38,417
| New | +$839K |
2024 Q3
0 quarters
|
|
285
Denali Therapeutics
DNLI
$3.03B
| $896K | 0.02% |
30,744
-773
| -2% | -$19.2K |
2023 Q2
5 quarters
|
|
286
Arcutis Biotherapeutics
ARQT
$3.3B
| $856K | 0.02% |
+92,019
| New | +$908K |
2024 Q3
0 quarters
|
|
287
Adaptive Biotechnologies
ADPT
$4.08B
| $846K | 0.02% |
165,274
+99,529
| +151% | +$434K |
2022 Q1
10 quarters
|
|
288
Bicycle Therapeutics
BCYC
$266M
| $814K | 0.02% |
35,976
-51,084
| -59% | -$1.18M |
2022 Q1
10 quarters
|
|
289
DELISTED
ACELYRIN
SLRN
| $807K | 0.02% |
163,724
+82,312
| +101% | +$425K |
2023 Q4
3 quarters
|
|
290
MoonLake Immunotherapeutics
MLTX
$909M
| $807K | 0.02% |
+16,000
| New | +$750K |
2024 Q3
0 quarters
|
|
291
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$822B
| $799K | 0.02% |
115,000
+15,000
| +15% | +$8.29M |
2024 Q2
1 quarter
|
|
292
Relay Therapeutics
RLAY
$3.94B
| $793K | 0.02% |
+112,048
| New | +$837K |
2024 Q3
0 quarters
|
|
293
Structure Therapeutics
GPCR
$1.71B
| $790K | 0.02% |
+18,000
| New | +$696K |
2024 Q3
0 quarters
|
|
294
DELISTED
Soleno Therapeutics
SLNO
| $784K | 0.02% |
15,536
+536
| +4% | +$25.7K |
2024 Q2
1 quarter
|
|
295
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $773K | 0.02% |
359,305
+81,202
| +29% | +$292K |
2023 Q4
3 quarters
|
|
296
Cullinan Oncology
CGEM
$962M
| $770K | 0.02% |
45,975
-16,000
| -26% | -$284K |
2023 Q2
5 quarters
|
|
297
D.R. Horton
DHI
$37.6B
| $759K | 0.02% |
3,978
-40,275
| -91% | -$7.08M |
2023 Q4
3 quarters
|
|
298
Bausch + Lomb
BLCO
$5.74B
| $752K | 0.02% |
+39,000
| New | +$645K |
2024 Q3
0 quarters
|
|
299
Ovid Therapeutics
OVID
$471M
| $741K | 0.02% |
628,290
+340,000
| +118% | +$355K |
2023 Q2
5 quarters
|
|
300
ON Semiconductor
ON
$29.6B
| $726K | 0.02% |
10,000
-5,000
| -33% | -$364K |
2023 Q1
6 quarters
|
|
Similar funds
FNBT
ACI
RC
A
CGL
CB
JCM
MPM
UBS O'Connor's Q3 2024 Portfolio in Review
As of Q3 2024, UBS O'Connor held 654 positions worth $4.05B, up 14% from $3.55B the previous quarter. Its ten largest holdings account for 56% of the portfolio.
UBS O'Connor deployed $330M of net new capital in Q3 2024, opening 120 new positions and adding to 131 existing holdings. Its largest new stake was Kellanova: 3,778,689 shares worth $305M.
By sector, the portfolio is most concentrated in Energy at 21% of assets, down from 27% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was US Steel, an estimated $20.2M trimmed.
- UBS O'Connor's largest Q3 2024 buy was Kellanova: 3,778,689 shares worth $305M.
- UBS O'Connor added most to Stericycle Inc in Q3 2024, an estimated $141M increase.
- UBS O'Connor's biggest Q3 2024 reduction was US Steel, cutting an estimated $20.2M.
- UBS O'Connor fully exited Equitrans Midstream Corporation Common Stock in Q3 2024, selling an estimated $149M.
- UBS O'Connor's ten largest holdings make up 56% of its $4.05B portfolio in Q3 2024.
- UBS O'Connor opened 120 new positions and closed 155 in Q3 2024.
- UBS O'Connor's portfolio value rose 14% quarter-over-quarter to $4.05B.
Based on UBS O'Connor's 13F filing for Q3 2024, filed 14 Nov 2024.